XORTX Therapeutics
XRTX
5 hedge funds and large institutions have $81.5K invested in XORTX Therapeutics in 2025 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 2 closing their positions.
35% more capital invested
Capital invested by funds: $60.2K → $81.5K (+$21.3K)
0.05% more ownership
Funds ownership: 0.34% → 0.39% (+0.05%)
17% less funds holding
Funds holding: 6 → 5 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$40.1K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$11.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$17.2K |
| 2 |
National Bank of Canada
Montreal,
Quebec, Canada
|
-$3.9K |
| 3 |
Raymond James Financial
St Petersburg,
Florida
|
-$453 |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$256 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Citadel Advisors
Miami,
Florida
| $69.9K | +$40.1K | +9,571 | +124% |
|
|
XT
2
XTX Topco
George Town,
Cayman Islands
| $11.2K | +$11.6K | +2,764 | New |
|
|
CA
3
Clearstead Advisors
Cleveland,
Ohio
| $225 | – | – | – |
|
|
4
UBS Group
Zurich,
Switzerland
| $190 | -$17.2K | -4,111 | -99% |
|
|
SS
5
SBI Securities
Tokyo,
Japan
| $1 | – | – | – |
|
|
6
National Bank of Canada
Montreal,
Quebec, Canada
| – | -$3.9K | -787 | Closed |
|
|
7
Raymond James Financial
St Petersburg,
Florida
| – | -$453 | -100 | Closed |
|
|
8
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$256 | -61 | -46% |
|
XRTX Hedge Fund Activity: Q3 2025 in Review
5 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in XORTX Therapeutics (XRTX) for Q3 2025, worth a combined $81.5K — up 35% from $60.2K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of XRTX and 1 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 1 added.
The largest buyer was Citadel Advisors, adding an estimated $40.1K. The largest seller was UBS Group, cutting an estimated $17.2K.
- 5 institutional investors held XORTX Therapeutics (XRTX) as of Q3 2025, down from 6 in Q2 2025.
- Funds reported $81.5K of XORTX Therapeutics stock for Q3 2025, up 35% quarter-over-quarter.
- 1 fund opened new XORTX Therapeutics positions in Q3 2025 and 2 closed out, a net change of -1 holder.
- The largest XORTX Therapeutics buyer in Q3 2025 was Citadel Advisors, an estimated $40.1K added.
- The largest XORTX Therapeutics seller in Q3 2025 was UBS Group, an estimated $17.2K sold.
Based on aggregated 13F filings for Q3 2025.